Medtronic is expanding its neuroscience operations by acquiring Sapiens Steering Brain Stimulation of the Netherlands for $200 million in cash.

The medtech major says the purchase of Sapiens SBS strengthens its capabilities “in an important, emerging frontier of medicine - the modulation of brain function” as it strives to become “the partner of choice for neurosurgeons and neuroscience centres around the world”. The privately-owned firm, which is based in Eindhoven, is developing a deep brain stimulation (DBS) system that features an advanced lead with 40 individual stimulation points.

Lothar Krinke, head of the brain modulation business at Medtronic, said the acquisition “broadens our neuroscience leadership position” with a technology that, “along with our comprehensive portfolio of DBS solutions, may one day transform the way physicians are able to treat patients with neurodegenerative diseases like Parkinson's disease and essential tremor”.

Medtronic is currently in the process of completing its $42.9 billion acquisition of Ireland-based Covidien.